Astellas Pharma Europe BV
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$496,934
Doctors Paid
11
Transactions
102
2024 Total
$12,008
Payment Breakdown by Category
Research$401,421 (80.8%)
Consulting$70,086 (14.1%)
Travel$25,196 (5.1%)
Food & Beverage$231.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $401,421 | 57 | 80.8% |
| Consulting Fee | $70,086 | 27 | 14.1% |
| Travel and Lodging | $25,196 | 14 | 5.1% |
| Food and Beverage | $231.09 | 4 | 0.0% |
Payments by Type
Research
$401,421
57 transactions
General
$95,513
45 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents | $180,883 | 0 | 8 |
| A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | $119,580 | 0 | 3 |
| A non-interventional post-authorization safety study (NI-PASS) of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from Transplant Pregnancy Registry International (TPRI) | $32,532 | 0 | 1 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer | $24,921 | 0 | 6 |
| A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder | $20,287 | 0 | 25 |
| A non interventional cohort study of the CLonal EVOlution of FLT3 mutations during disease progression in patients with acute myeloid leukemia CLEVO | $11,865 | 0 | 11 |
| A PHASE 2 OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY OF CONTINUED ADMINISTRATION OF MDV3100 IN SUBJECTS WITH PROSTATE CANCER WHO SHOWED BENEFIT FROM PRIOR EXPOSURE TO MDV3100 | $6,500 | 0 | 1 |
| A MULTICENTER COHORT STUDY OF THE SHORT AND LONG-TERM SAFETY OF MICAFUNGIN AND OTHER PARENTERAL ANTIFUNGAL AGENTS | $4,124 | 0 | 1 |
| A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder | $730.00 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatric Urology | $46,201 | 2 | $23,101 |
| Specialist | $19,875 | 1 | $19,875 |
| Urology | $11,587 | 3 | $3,862 |
| Pediatric Cardiology | $11,200 | 1 | $11,200 |
| Clinical Pharmacology | $3,674 | 1 | $3,674 |
| Hematology & Oncology | $2,592 | 2 | $1,296 |
| Student in an Organized Health Care Education/Training Program | $384.96 | 1 | $384.96 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Beth Drzewiecki, Md, MD | Pediatric Urology | Boston, MA | $44,799 | $0 |
| Dr. Michael Weber, Md, MD | Specialist | New York, NY | $19,875 | $0 |
| Elaine Urbina, M.d, M.D | Pediatric Cardiology | Cincinnati, OH | $11,200 | $0 |
| Dr. Elizabeth Mueller | Urology | Maywood, IL | $6,825 | $0 |
| Dr. Israel Franco, Md, MD | Urology | New Haven, CT | $4,690 | $0 |
| Philip Walson, Md, MD | Clinical Pharmacology | Cincinnati, OH | $3,674 | $0 |
| Elaine Lam, Md, MD | Hematology & Oncology | Aurora, CO | $2,520 | $0 |
| Dr. William Kennedy, Md, MD | Pediatric Urology | Palo Alto, CA | $1,403 | $0 |
| Dr. Andrew Stec, Md, MD | Student in an Organized Health Care Education/Training Program | Charleston, SC | $384.96 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $71.55 | $0 |
| Dr. Ana Aparicio | Hematology & Oncology | Houston, TX | $71.55 | $0 |
Ad
Top Products
- Micafungin $180,883
- Enzalutamide $119,580
Payment Categories
- Food & Beverage $231.09
- Consulting $70,086
- Travel & Lodging $25,196
- Research $401,421
About Astellas Pharma Europe BV
Astellas Pharma Europe BV has made $496,934 in payments to 11 healthcare providers, recorded across 102 transactions in the CMS Open Payments database. In 2024, the company paid $12,008. The top product by payment volume is Micafungin ($180,883).
Payments were distributed across 7 medical specialties. The top specialty by payment amount is Pediatric Urology ($46,201 to 2 doctors).
Payment categories include: Food & Beverage ($231.09), Consulting ($70,086), Research ($401,421), Travel & Lodging ($25,196).